OP-101 is a hydroxyl dendrimer therapeutic (HDT) with N-acetyl cysteine (NAC) that selectively targets reactive macrophages and microglia, immune cells that play key roles in directing and controlling inflammation in multiple diseases.
D-4517.2 is an HDT with potent anti- angiogenic activity that crosses the blood-retinal barrier and selectively targets reactive inflammatory and retinal pigment epithelial cells. D-4517.2 has the potential to change the current treatment paradigm for neovascular age-related macular degeneration (wet-AMD) and diabetic macular edema (DME) by offering a subcutaneous route of administration rather than delivery via intravitreal injection.
OP-801 is a hydroxyl dendrimer (HD) imaging agent that selectively targets reactive macrophages and microglia. OP-801 will allow us to visualize HD drug delivery in hard to access regions such as the brain, joints and lungs. We are currently studying OP-801’s ability to cross the blood-brain barrier in regions of neuroinflammation; this will inform HD therapeutic delivery in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer’s disease and Parkinson’s disease.
D6-483 is an HD imaging agent with the ability to cross the blood-brain barrier and be used in patient selection for potential neuro-oncology treatments.
Engine Rapidly Delivers Breakthrough Therapies
Opening the Therapeutic Index
- Uptake only in reactive and diseased cells (no off-target toxicity)
- Renal excretion – no liver uptake or metabolism
- Rapid clearance (<1-2 days in humans) with retention in cells for up to a month (less systemic exposure)
- Human demonstration of HDT with drug that is normally toxic
- D-4517.2, potent anti-angiogenic agent, no observed adverse effects in humans at the therapeutically effective dose
- HD-Aurastatin E (D-4532) did not result in observed toxicity at 10x doses of Aurastatin E that were lethal in mice after systemic administration